Rifaximin on Visceral Hypersensitivity

NCT03462966 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

4

Enrollment

OTHER

Sponsor class

Stopped recruitment challenges

Conditions

Visceral Hypersensitivity
Irritable Bowel Syndrome

Interventions

DRUG: Rifaximin

Sponsor

Cedars-Sinai Medical Center

Collaborators

[object Object]